{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T01:26:19Z","timestamp":1794446779571,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP223fa627001"],"award-info":[{"award-number":["JP223fa627001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP243fa627005"],"award-info":[{"award-number":["JP243fa627005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JSPS KAKENHI","award":["JP22K16383"],"award-info":[{"award-number":["JP22K16383"]}]},{"name":"RIKEN Center for Computational Science, Japan","award":["hp230052"],"award-info":[{"award-number":["hp230052"]}]},{"DOI":"10.13039\/100031751","name":"RIKEN Center for Computational Science","doi-asserted-by":"publisher","award":["hp240149"],"award-info":[{"award-number":["hp240149"]}],"id":[{"id":"10.13039\/100031751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["23HA2021"],"award-info":[{"award-number":["23HA2021"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike contains multiple classes of antibody epitopes that are associated with diverse neutralizing activities. Although both natural infection and vaccination robustly elicit RBD-reactive and neutralizing antibodies, the spike antigenic structures presented to the immune system may differ, leading to qualitative differences in the antibody responses. Using large and well-controlled cohorts, we show that the neutralizing potency index (NPI), calculated as the ratio of neutralizing titer to RBD IgG titer, is approximately fivefold lower in vaccine recipients than in convalescent individuals, independent of disease severity, comorbidities, or demographic factors. This reduction in NPI is associated with enhanced antibody targeting to non-neutralizing, yet conserved and structurally occluded RBD epitope. Molecular dynamics (MD) simulations together with the binding assay demonstrate that the occluded epitope is allosterically exposed by stabilizing mutations introduced into the vaccine spike antigen, a process mediated by a highly extended RBD-up conformation. Collectively, our findings demonstrate that RBD conformational modulation by stabilizing mutations shapes vaccine antigenicity and likely alters the epitope landscape of antibody responses.<\/jats:p>","DOI":"10.1038\/s41541-026-01464-2","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:36:50Z","timestamp":1777120610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes"],"prefix":"10.1038","volume":"11","author":[{"given":"Shintaro","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Kotaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham M.","family":"Dokainish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saya","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Terahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Isogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Shinkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"1464_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41577-023-00858-w","volume":"23","author":"DR Burton","year":"2023","unstructured":"Burton, D. R. Antiviral neutralizing antibodies: from in vitro to in vivo activity. Nat. Rev. Immunol. 23, 720\u2013734 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1464_CR2","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1464_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1464_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","volume":"375","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43\u201350 (2022).","journal-title":"Science"},{"key":"1464_CR5","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428 (2021).","journal-title":"Vaccine"},{"key":"1464_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"1464_CR7","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","volume":"383","author":"EE Walsh","year":"2020","unstructured":"Walsh, E. E. et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1464_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. 383, 1920\u20131931 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1464_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"1464_CR10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41579-025-01185-8","volume":"23","author":"B Chen","year":"2025","unstructured":"Chen, B., Farzan, M. & Choe, H. SARS-CoV-2 spike protein: structure, viral entry and variants. Nat. Rev. Microbiol. 23, 455\u2013468 (2025).","journal-title":"Nat. Rev. Microbiol."},{"key":"1464_CR11","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280.e8 (2020).","journal-title":"Cell"},{"key":"1464_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"1464_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292.e6 (2020).","journal-title":"Cell"},{"key":"1464_CR14","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1016\/j.cell.2021.07.025","volume":"184","author":"P Tong","year":"2021","unstructured":"Tong, P. et al. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. Cell 184, 4969\u20134980.e15 (2021).","journal-title":"Cell"},{"key":"1464_CR15","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1126\/science.abd5223","volume":"370","author":"B Turo\u0148ov\u00e1","year":"2020","unstructured":"Turo\u0148ov\u00e1, B. et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science 370, 203\u2013208 (2020).","journal-title":"Science"},{"key":"1464_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"1464_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"1464_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"1464_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2205784119","volume":"119","author":"M Yuan","year":"2022","unstructured":"Yuan, M. et al. A broad and potent neutralization epitope in SARS-related coronaviruses. Proc. Natl. Acad. Sci. USA 119, e2205784119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1464_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"1464_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.cell.2020.09.037","volume":"183","author":"L Piccoli","year":"2020","unstructured":"Piccoli, L. et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024\u20131042.e21 (2020).","journal-title":"Cell"},{"key":"1464_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35949-8","volume":"14","author":"K-YA Huang","year":"2023","unstructured":"Huang, K.-Y. A. et al. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2. Nat. Commun. 14, 311 (2023).","journal-title":"Nat. Commun."},{"key":"1464_CR23","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41594-020-0478-5","volume":"27","author":"X Xiong","year":"2020","unstructured":"Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934\u2013941 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1464_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2020.12.015","volume":"184","author":"WF Garcia-Beltran","year":"2021","unstructured":"Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476\u2013488.e11 (2021).","journal-title":"Cell"},{"key":"1464_CR25","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1016\/j.immuni.2021.06.015","volume":"54","author":"S Moriyama","year":"2021","unstructured":"Moriyama, S. et al. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. Immunity 54, 1841\u20131852.e4 (2021).","journal-title":"Immunity"},{"key":"1464_CR26","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1016\/j.cell.2021.06.005","volume":"184","author":"F Amanat","year":"2021","unstructured":"Amanat, F. et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. Cell 184, 3936\u20133948.e10 (2021).","journal-title":"Cell"},{"key":"1464_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-021-04060-7","volume":"600","author":"A Cho","year":"2021","unstructured":"Cho, A. et al. Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. Nature 600, 517\u2013522 (2021).","journal-title":"Nature"},{"key":"1464_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39890-8","volume":"14","author":"S Moriyama","year":"2023","unstructured":"Moriyama, S. et al. Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants. Nat. Commun. 14, 4198 (2023).","journal-title":"Nat. Commun."},{"key":"1464_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"1464_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41594-022-00735-5","volume":"29","author":"SM Costello","year":"2022","unstructured":"Costello, S. M. et al. The SARS-CoV-2 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat. Struct. Mol. Biol. 29, 229\u2013238 (2022).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1464_CR31","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"1464_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41586-020-2456-9","volume":"584","author":"DF Robbiani","year":"2020","unstructured":"Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature 584, 437\u2013442 (2020).","journal-title":"Nature"},{"key":"1464_CR33","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.immuni.2020.10.023","volume":"53","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity. Immunity 53, 1272\u20131280.e5 (2020).","journal-title":"Immunity"},{"key":"1464_CR34","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"1464_CR35","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","volume":"185","author":"Z Zhang","year":"2022","unstructured":"Zhang, Z. et al. Humoral and cellular immune memory to four COVID-19 vaccines. Cell 185, 2434\u20132451.e17 (2022).","journal-title":"Cell"},{"key":"1464_CR36","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","volume":"54","author":"M-G Alameh","year":"2021","unstructured":"Alameh, M.-G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877\u20132892.e7 (2021).","journal-title":"Immunity"},{"key":"1464_CR37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","volume":"23","author":"S Tahtinen","year":"2022","unstructured":"Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532\u2013542 (2022).","journal-title":"Nat. Immunol."},{"key":"1464_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi9915","volume":"13","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Sci. Transl. Med. 13, eabi9915 (2021).","journal-title":"Sci. Transl. Med."},{"key":"1464_CR39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41586-023-06487-6","volume":"621","author":"A Addetia","year":"2023","unstructured":"Addetia, A. et al. Neutralization, effector function and immune imprinting of Omicron variants. Nature 621, 592\u2013601 (2023).","journal-title":"Nature"},{"key":"1464_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-021-04017-w","volume":"599","author":"R Yamin","year":"2021","unstructured":"Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465\u2013470 (2021).","journal-title":"Nature"},{"key":"1464_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31615-7","volume":"13","author":"JB Case","year":"2022","unstructured":"Case, J. B. et al. Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains. Nat. Commun. 13, 3824 (2022).","journal-title":"Nat. Commun."},{"key":"1464_CR42","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.xcrm.2022.100510","volume":"3","author":"SI Richardson","year":"2022","unstructured":"Richardson, S. I. et al. SARS-CoV-2 beta and delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep. Med. 3, 100510 (2022).","journal-title":"Cell Rep. Med."},{"key":"1464_CR43","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/j.jinf.2022.06.033","volume":"85","author":"G Martin-Blondel","year":"2022","unstructured":"Martin-Blondel, G. et al. Sotrovimab to prevent severe COVID-19 in high-risk patients infected with Omicron BA.2. J. Infect. 85, e104\u2013e108 (2022).","journal-title":"J. Infect."},{"key":"1464_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40121-022-00755-0","volume":"12","author":"MM Cheng","year":"2023","unstructured":"Cheng, M. M. et al. Real-world effectiveness of sotrovimab for the early treatment of COVID-19 during SARS-CoV-2 Delta and Omicron waves in the USA. Infect. Dis. Ther. 12, 607\u2013621 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"1464_CR45","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310.e20 (2020).","journal-title":"Cell"},{"key":"1464_CR46","doi-asserted-by":"crossref","unstructured":"Kotaki, R. et al. SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci. Immunol. 7, eabn8590 (2022).","DOI":"10.1126\/sciimmunol.abn8590"},{"key":"1464_CR47","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.cell.2022.04.009","volume":"185","author":"RR Goel","year":"2022","unstructured":"Goel, R. R. et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell 185, 1875\u20131887 (2022).","journal-title":"Cell"},{"key":"1464_CR48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41586-022-04778-y","volume":"607","author":"F Muecksch","year":"2022","unstructured":"Muecksch, F. et al. Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. Nature 607, 128\u2013134 (2022).","journal-title":"Nature"},{"key":"1464_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.immuni.2022.04.002","volume":"55","author":"A Sokal","year":"2022","unstructured":"Sokal, A. et al. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant. Immunity 55, 1096\u20131104.e4 (2022).","journal-title":"Immunity"},{"key":"1464_CR50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20221786","volume":"220","author":"T Inoue","year":"2023","unstructured":"Inoue, T. et al. Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees. J. Exp. Med. 220, e20221786 (2023).","journal-title":"J. Exp. Med."},{"key":"1464_CR51","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41586-022-05609-w","volume":"613","author":"D Schaefer-Babajew","year":"2023","unstructured":"Schaefer-Babajew, D. et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature 613, 735\u2013742 (2023).","journal-title":"Nature"},{"key":"1464_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19146-5","volume":"11","author":"AG Wrobel","year":"2020","unstructured":"Wrobel, A. G. et al. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein. Nat. Commun. 11, 5337 (2020).","journal-title":"Nat. Commun."},{"key":"1464_CR53","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41557-021-00707-0","volume":"13","author":"MI Zimmerman","year":"2021","unstructured":"Zimmerman, M. I. et al. SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome. Nat. Chem. 13, 651\u2013659 (2021).","journal-title":"Nat. Chem."},{"key":"1464_CR54","doi-asserted-by":"publisher","unstructured":"Dokainish, H. M. et al. The inherent flexibility of receptor binding domains in SARS-CoV-2 spike protein. Elife https:\/\/doi.org\/10.7554\/eLife.75720 (2022).","DOI":"10.7554\/eLife.75720"},{"key":"1464_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28882-9","volume":"13","author":"G Ye","year":"2022","unstructured":"Ye, G., Liu, B. & Li, F. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. Nat. Commun. 13, 1214 (2022).","journal-title":"Nat. Commun."},{"key":"1464_CR56","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.molcel.2022.03.028","volume":"82","author":"SM-C Gobeil","year":"2022","unstructured":"Gobeil, S. M.-C. et al. Structural diversity of the SARS-CoV-2 Omicron spike. Mol. Cell 82, 2050\u20132068.e6 (2022).","journal-title":"Mol. Cell"},{"key":"1464_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100631","volume":"3","author":"T Takano","year":"2022","unstructured":"Takano, T. et al. Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine. Cell Rep. Med. 3, 100631 (2022).","journal-title":"Cell Rep. Med."},{"key":"1464_CR58","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp9927","volume":"16","author":"R Kotaki","year":"2024","unstructured":"Kotaki, R. et al. Repeated Omicron exposures redirect SARS-CoV-2-specific memory B cell evolution toward the latest variants. Sci. Transl. Med. 16, eadp9927 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1464_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37128-1","volume":"14","author":"T Takano","year":"2023","unstructured":"Takano, T. et al. Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain. Nat. Commun. 14, 1451 (2023).","journal-title":"Nat. Commun."},{"key":"1464_CR60","doi-asserted-by":"publisher","first-page":"7128","DOI":"10.1021\/acs.jpcb.0c04553","volume":"124","author":"H Woo","year":"2020","unstructured":"Woo, H. et al. Developing a fully glycosylated full-length SARS-CoV-2 spike protein model in a viral membrane. J. Phys. Chem. B 124, 7128\u20137137 (2020).","journal-title":"J. Phys. Chem. B"},{"key":"1464_CR61","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S., Kim, T., Iyer, V. G. & Im, W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29, 1859\u20131865 (2008).","journal-title":"J. Comput. Chem."},{"key":"1464_CR62","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1021\/acs.jpcb.4c02096","volume":"128","author":"J Jung","year":"2024","unstructured":"Jung, J. et al. GENESIS 2.1: High-performance molecular dynamics software for enhanced sampling and free-energy calculations for atomistic, coarse-grained, and quantum mechanics\/molecular mechanics models. J. Phys. Chem. B 128, 6028\u20136048 (2024).","journal-title":"J. Phys. Chem. B"},{"key":"1464_CR63","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1016\/j.bpj.2022.11.025","volume":"122","author":"HM Dokainish","year":"2023","unstructured":"Dokainish, H. M. & Sugita, Y. Structural effects of spike protein D614G mutation in SARS-CoV-2. Biophys. J. 122, 2910\u20132920 (2023).","journal-title":"Biophys. J."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01464-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01464-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T06:42:56Z","timestamp":1782888176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-026-01464-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1464"],"URL":"https:\/\/doi.org\/10.1038\/s41541-026-01464-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"22 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"128"}}